Ubs Asset Management Americas Inc Supernus Pharmaceuticals, Inc. Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 80,196 shares of SUPN stock, worth $2.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

80,196

Previous 92,539 13.34%

Holding current value

$2.9 Million

Previous $2.48 Million 1.01%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$25.77 - $35.16 $318,079 - $433,979	-12,343 Reduced 13.34%	80,196 $2.5 Million
Q2 2024 Aug 13, 2024	BUY	$25.99 - $33.85 $1.07 Million - $1.39 Million	41,172 Added 80.15%	92,539 $2.48 Million
Q4 2023 Feb 14, 2024	BUY	$22.72 - $29.68 $82,541 - $107,827	3,633 Added 7.61%	51,367 $1.49 Million
Q3 2023 Nov 13, 2023	SELL	$27.57 - $32.91 $216,369 - $258,277	-7,848 Reduced 14.12%	47,734 $1.32 Million
Q1 2023 May 15, 2023	SELL	$34.93 - $42.03 $54,490 - $65,566	-1,560 Reduced 2.73%	55,582 $2.01 Million
Q4 2022 Feb 14, 2023	SELL	$31.09 - $37.88 $48,344 - $58,903	-1,555 Reduced 2.65%	57,142 $2.04 Million
Q3 2022 Nov 14, 2022	BUY	$28.79 - $35.41 $174,928 - $215,151	6,076 Added 11.55%	58,697 $1.99 Million
Q2 2022 Aug 12, 2022	SELL	$25.33 - $34.25 $23,911 - $32,332	-944 Reduced 1.76%	52,621 $1.52 Million
Q1 2022 May 16, 2022	BUY	$28.51 - $32.9 $273,382 - $315,478	9,589 Added 21.81%	53,565 $1.73 Million
Q4 2021 Feb 14, 2022	SELL	$26.37 - $34.22 $34,518 - $44,793	-1,309 Reduced 2.89%	43,976 $1.28 Million
Q2 2021 Aug 16, 2021	BUY	$26.72 - $33.19 $70,941 - $88,119	2,655 Added 6.23%	45,285 $1.39 Million
Q2 2020 Aug 14, 2020	BUY	$17.09 - $24.89 $198,978 - $289,794	11,643 Added 37.57%	42,630 $1.01 Million
Q1 2020 May 15, 2020	SELL	$14.45 - $24.69 $146,147 - $249,714	-10,114 Reduced 24.61%	30,987 $557,000
Q4 2019 Feb 14, 2020	SELL	$19.93 - $29.13 $130,880 - $191,296	-6,567 Reduced 13.78%	41,101 $974,000
Q3 2019 Nov 14, 2019	BUY	$25.47 - $33.37 $193,750 - $253,845	7,607 Added 18.99%	47,668 $1.31 Million
Q2 2019 Aug 15, 2019	SELL	$29.96 - $38.87 $3.9 Million - $5.06 Million	-130,099 Reduced 76.46%	40,061 $0
Q1 2019 May 14, 2019	BUY	$32.77 - $41.99 $74,224 - $95,107	2,265 Added 1.35%	170,160 $0
Q4 2018 Feb 13, 2019	SELL	$30.84 - $49.51 $286,071 - $459,254	-9,276 Reduced 5.24%	167,895 $5.58 Million
Q3 2018 Nov 14, 2018	BUY	$42.7 - $56.55 $332,504 - $440,354	7,787 Added 4.6%	177,171 $0
Q2 2018 Aug 14, 2018	SELL	$44.1 - $59.85 $536,829 - $728,554	-12,173 Reduced 6.7%	169,384 $0
Q1 2018 May 14, 2018	SELL	$37.15 - $46.9 $2.21 Million - $2.79 Million	-59,519 Reduced 24.69%	181,557 $0
Q4 2017 Feb 09, 2018	SELL	$36.4 - $42.6 $200,018 - $234,087	-5,495 Reduced 2.23%	241,076 $0
Q3 2017 Nov 13, 2017	BUY	$36.75 - $49.65 $9.06 Million - $12.2 Million	246,571	246,571 $0

Others Institutions Holding SUPN

# of Institutions

282

Shares Held

60.9M

Call Options Held

27.7K

Put Options Held

11.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.94B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Supernus Pharmaceuticals, Inc. Transaction History